Sinonasal Intervention Reduces the Need for Pressure Equalization Tube Placement in Atopic Adults
The Laryngoscope · 2025
DOI: 10.1002/lary.32207 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Lawrance Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Middle Ear Ventilation, Eustachian Tube, Sinusitis, Hypersensitivity, Immediate. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
To determine the impact of management of upper airway atopic disease on middle ear and eustachian tube function in adults.
Methods
The TriNetX Research Network was queried to construct cohorts of adult patients with atopic disorders of the upper airway (defined by ICD‐10 codes for asthma, allergic rhinitis, and chronic rhinosinusitis with nasal polyposis) with concurrent eustachian tube dysfunction (ETD) undergoing medical or surgical intervention for their atopic disease, including monoclonal antibody (mAb) therapy (e.g., dupilumab, mepolizumab, omalizumab), topical nasal steroid spray (fluticasone propionate), functional endoscopic sinus surgery (FESS), septoplasty with inferior turbinate submucosal resection (BITSMR), and allergy immunotherapy. The primary measured outcome was the difference in the rate of pressure equalization tube (PET) placement before and after each intervention.
Results
FESS demonstrated an absolute risk reduction (ARR) of 10.0% ( p < 0.05, 95% confidence interval [CI] 8.9%–11.1%), septoplasty/BITSMR 7.5% ( p < 0.05, 95% CI 6.3%–8.7%), mAb 5.5% ( p < 0.05, 95% CI 4.1%–6.8%), nasal steroid spray (fluticasone proprionate) 0.9% ( p < 0.05, 95% CI 0.8%–1.0%), and allergy immunotherapy 2.4% ( p < 0.05, 95% CI 1.5%–3.2%). Individually, the three mAb—dupilumab, mepolizumab, and omalizumab—exhibited ARR of 6.5% ( p < 0.05%, 95% CI 4.8%–8.3%), 6.8% ( p < 0.05, 95% CI 2.6%–11.0%), and 3.4% ( p < 0.05, 95% CI 1.4%–5.4%), respectively, without significant differences in rates of PET placement among the three ( p = 0.18).
Conclusion
Management of upper airway atopic disorders via both medical and surgical intervention is associated with improvement in middle function as measured by the need for PET placement. Level of Evidence 3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
- School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
ORCID-Profile: Lawrance Lee, Elizabeth Mastoloni
Zitieren
APA
Lee, L., Bentan, M. A., Mastoloni, E., & Schuman, T. A. (2025). Sinonasal Intervention Reduces the Need for Pressure Equalization Tube Placement in Atopic Adults. The Laryngoscope. https://doi.org/10.1002/lary.32207
Vancouver
Lee L, Bentan MA, Mastoloni E, Schuman TA. Sinonasal Intervention Reduces the Need for Pressure Equalization Tube Placement in Atopic Adults. The Laryngoscope. 2025. doi:10.1002/lary.32207
BibTeX
@article{Lee2025,
author = {Lee, Lawrance and Bentan, Mihai A and Mastoloni, Elizabeth and Schuman, Theodore A},
title = {Sinonasal Intervention Reduces the Need for Pressure Equalization Tube Placement in Atopic Adults},
journal = {The Laryngoscope},
year = {2025},
doi = {10.1002/lary.32207}
}
EUVIMED